可复制性单纯疱疹病毒在抗肿瘤方面的应用

Applications of Replication-Competent Herpes Simplex Viruses in Anti-Tumor Research

单纯疱疹病毒是肿瘤生物治疗中常用的病毒载体之一,可复制性单纯疱疹病毒以其溶瘤效率高、特异性好、可行性强成为近年来研究的热点。其中对溶瘤性单纯疱疹病毒突变株G207的研究开展得早,其溶瘤效果、靶向性及安全性都得到了确认,这也带动了可复制性单疱病毒应用的发展,目前已研究出多种溶瘤单纯疱疹病毒突变株。本文就近几年可复制性单纯疱疹病毒在抗肿瘤方面的研究现状加以综述,以探讨其临床治疗肿瘤的潜在价值及可行性。

Herpes simplex virus is one of the most widely used viral vector, and replication-competent oncolytic herpes simplex virus has become the spotlight for its high oncolytic efficiency, specificity and better feasibility in recent years. The mutated oncolytic herpes simplex virus G207 was affirmed about its oncolytic efficacy, targeting effects and safety, that bring alone the development of other replication-competent herpes simplex viruses. Now, there are several types of the mutated oncolytic herpes simplex viruses applying both in laboratory and clinical experiments. This review summarized the lately advances in anti-tumor research of replication-competent oncolytic herpes simplex virus targeting to the tumor cells, and discussed its potential value and feasibility in clinical tumor therapy.